Related Experiment Video
Updated: Aug 7, 2026

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Secondary hormonal manipulations in prostate cancer
1Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA. ryanc@medicine.ucsf.edu
Abstract:
Targeting AIPC with therapies that affect the mechanisms of androgen receptor signaling despite a castrate testosterone milieu is an active and growing area of clinical research. At present, for patients with AIPC, the data support the maintenance of the castrate state, recognition of the AAWD phenomenon,the sequential use of oral antiandrogens, and a trial of estrogens or adrenal androgen-targeted therapies. Novel agents are being developed that seek to prolong the duration of clinical responses and the overall response rate.
Insights
Treating advanced androgen receptor pathway-inhibited prostate cancer (AIPC) involves managing castrate testosterone levels and exploring various antiandrogen therapies. Research is ongoing for novel agents to improve treatment response and duration in AIPC patients.
Area of Science:
- Oncology
- Urology
- Endocrinology
Background:
- Advanced prostate cancer often progresses despite castrate testosterone levels.
- Androgen receptor signaling remains crucial even in a low-testosterone environment.
- Understanding resistance mechanisms is key for effective AIPC treatment.
Purpose of the Study:
- To review current therapeutic strategies for advanced androgen receptor pathway-inhibited prostate cancer (AIPC).
- To highlight the importance of managing castrate testosterone milieu and related phenomena.
- To discuss emerging novel agents targeting AIPC.
Main Methods:
- Review of clinical research data on AIPC therapies.
- Analysis of treatment sequences and emerging drug development.
- Focus on therapies affecting androgen receptor signaling.
Main Results:
- Current data support maintaining castrate state and recognizing the androgen-acting androgen-deprived (AAWD) phenomenon.
- Sequential oral antiandrogens, estrogens, or adrenal androgen-targeted therapies are indicated.
- Novel agents are under development to enhance response rates and duration.
Conclusions:
- Managing AIPC requires a multi-faceted approach targeting androgen receptor signaling.
- Sequential therapies and novel agents show promise for improving outcomes.
- Continued research is vital for advancing AIPC treatment strategies.
Related Concept Videos
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Testosterone: Functions and Regulation
Regulation of Hormone Secretion
Humoral stimuli,...
Secondary Messengers in Hormone Action
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
Hormones of the Pituitary Gland
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.

